Background/Aims: Proteinuria is associated with oxidant stress and inflammation. Hyperbaric oxygen (HBO) treatment has anti-inflammatory and anti-oxidant effects. The aim of the study was to investigate the benefits of HBO treatment on an experimental nephrotic syndrome model. Methods: 50 male Sprague-Dawley rats weighing 255 ± 39 g were housed. Forty rats were injected 6 mg/kg adriamycin into tail veins under anesthesia to induce nephrosis, while 10 rats were spared as sham control. After the stabilization of proteinuria at the sixth week, the rats were treated for 6 weeks by losartan (n = 10, 30 mg/kg/day), HBO (n = 10, 2.8 atmosphere absolute, 90 min/day), HBO + losartan (n = 10) and vehicle (n = 10). Protein carbonyl (PCO), superoxide dismutase (SOD) and glutathione peroxidase (GPx) were analyzed from tissue specimens. Biochemical markers were studied from venous samples and 24-hour urine was collected for proteinuria. The surviving animals at 12 weeks (vehicle group (n = 6), HBO (n = 6), losartan (n = 8), HBO + losartan (n = 10) were sacrificed. Glomerular sclerosis, tubulointerstitial and blood vessel changes were determined by semiquantitative scoring. Results: The PCO levels increased (p < 0.001), and the GPx and SOD levels decreased (p < 0.001 for both) in the nephrotic rats. In losartan and HBO groups GPx levels increased (p = 0.001, p = 0.002 respectively), but PCO and SOD levels did not change. The combination of HBO with losartan significantly increased the GPx and SOD levels (p = 0.001 for both) and decreased PCO levels (p = 0.005). HBO but not losartan significantly reduced proteinuria (p < 0.001). The combination of HBO and losartan reduced proteinuria better than the single losartan regime (p < 0.001). The effect of the combination was also noticed on the histological examination of the kidneys. The activities, appetites, weight gains, and improvement of edema were better in the HBO combined with losartan regime. Conclusions: These results indicate that the addition of HBO therapy to a conventional regime, angiotensin receptor blockers, has significant benefits in the management of proteinuria. Future clinical studies are needed to elucidate the role of HBO and other antioxidant strategies in the treatment of proteinuria.

1.
Burton C, Harris KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996;27:765&ndash;775.
[PubMed]
2.
D&rsquo;Amico G, Bazzi C: Pathophysiology of proteinuria. Kidney Int 2003;63:809&ndash;825.
[PubMed]
3.
Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM: Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl 2004;S76&ndash;S89.
4.
Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799&ndash;812.
[PubMed]
5.
Venkat KK: Proteinuria and microalbuminuria in adults: significance, evaluation, and treatment. South Med J 2004;97:969&ndash;979.
[PubMed]
6.
Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M: Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986;29:502&ndash;510.
[PubMed]
7.
Fogo, AB: Animal models of FSGS: lessons for pathogenesis and treatment. Semin Nephrol 2003 23:161&ndash;171.
[PubMed]
8.
Sternberg, SS: Cross-striated fibrils and other ultrastructural alterations in glomeruli of rats with daunomycin nephrosis. Lab Invest 1970;23:39&ndash;51.
[PubMed]
9.
Powis G: Free radical formation by antitumor quinones. Free Radic Biol Med 1989;6:63&ndash;101.
[PubMed]
10.
Raats CJ, Bakker MA, van den Born J, Berden JH: Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997;272:26734&ndash;26741.
[PubMed]
11.
Barbey MM, Fels LM, Soose M, Poelstra K, Gwinner W, Bakker W, Stolte H: Adriamycin affects glomerular renal function: evidence for the involvement of oxygen radicals. Free Radic Res Commun 1989;7:195&ndash;203.
[PubMed]
12.
Mazu&egrave; G, Atropoulos M, Imondi A, Castellino S, Brughera M, Podest&agrave; A: Anthracyclines: a review of general and special toxicity studies. Int J Oncol 1995;7:713&ndash;726.
13.
Hink J, Jansen E: Are superoxide and/or hydrogen peroxide responsible for some of the beneficial effects of hyperbaric oxygen therapy? Med Hypotheses 2001;57:764&ndash;769.
[PubMed]
14.
Gill AL, Bell CN: Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM 2004;97:385&ndash;395.
[PubMed]
15.
Thom SR: Antagonism of carbon monoxide-mediated brain lipid peroxidation by hyperbaric oxygen. Toxicol Appl Pharmacol 1990, vol. 105, pp 340&ndash;344.
[PubMed]
16.
Chen MF, Chen HM, Ueng SW, Shyr MH: Hyperbaric oxygen pretreatment attenuates hepatic reperfusion injury. Liver 1998;18:110&ndash;116.
[PubMed]
17.
Thom SR: Functional inhibition of leukocyte B2 integrins by hyperbaric oxygen in carbon monoxide-mediated brain injury in rats. Toxicol Appl Pharmacol, 1993, vol. 123, pp 248&ndash;256.
[PubMed]
18.
Kusumoto Y, Takebayashi S, Taguchi T, Harada T, Naito S: Long-term prognosis and prognostic indices of IgA nephropathy in juvenile and in adult Japanese. Clin Nephrol 1987;28:118&ndash;124.
[PubMed]
19.
Bader H, Meyer DS: The size of the juxtaglomerular apparatus in diabetic glomerulosclerosis and its correlation with arteriolosclerosis and arterial hypertension: a morphometric light microscopic study on human renal biopsies. Clin Nephrol 1977;8:308&ndash;311.
[PubMed]
20.
Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H: Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33:115&ndash;122.
[PubMed]
21.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin-phenol reagent. J Biol Chem 1951;193:265&ndash;275.
[PubMed]
22.
Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stantman ER: Determination of carbonyl content in oxidatively modified proteins; in Packer L, Glazer AN (eds): Methods in Enzymology. Oxygen Radicals in Biological Systems. San Diego, Academic Press, 1990, vol 186, pp 464&ndash;478.
23.
Sun Y, Oberley LW, Ying L: A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497&ndash;500.
[PubMed]
24.
Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterisation of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158&ndash;169.
[PubMed]
25.
Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994;45:S145&ndash;S149.
26.
Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 1994;45:S174&ndash;S178.
27.
Washio M, Nanishi F, Okuda S, Onoyama K, Fujishima M: Alpha tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure. Nephron 1994;68:347&ndash;352.
[PubMed]
28.
Okasora T, Takikawa T, Utsunomiya Y, Senoh I, Hayashibara H, Shiraki K, Kasagi T, Shimizu F: Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron 1992;60:199&ndash;203.
[PubMed]
29.
Yilmaz MI, Saglam M, Caglar K, Cakir E,Ozgurtas T,Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A: The endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005;80:1660&ndash;1666.
[PubMed]
30.
Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, Acikel C, Gulec B, Kozak O, Oner K: Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005;25:250&ndash;255.
[PubMed]
31.
D Jamieson: Oxygen toxicity and reactive oxygen metabolites in mammals. Free Radic Biol Med 1989;7:87&ndash;108.
[PubMed]
32.
Narkowicz CK, Vial JH, McCartney PW: Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radic Res Commun 1993;19:71&ndash;80.
[PubMed]
33.
Benedetti S, Lamorgese A, Piersantelli M, Pagliarani S, Benvenuti F, Canestrari F: Oxidative stress and antioxidant status in patients undergoing prolonged exposure to hyperbaric oxygen. Clin Biochem 2004;37:312&ndash;317.
[PubMed]
34.
Oter S, Edremitlioglu M, Korkmaz A, Coskun O, Kilic D, Kisa U, Yaren H, Bilgic H: Effects of hyperbaric oxygen treatment on liver functions, oxidative status and histology in septic rats. Intensive Care Med 2005;31:1262&ndash;1268.
[PubMed]
35.
Ozden TA, Uzun H, Bohloli M, Toklu AS, Paksoy M, Simsek G, Durak H, Issever H, Ipek T: The effects of hyperbaric oxygen treatment on oxidant and antioxidants levels during liver regeneration in rats. Tohoku J Exp Med 2004;203:253&ndash;265.
[PubMed]
36.
Giordano FJ: Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005;115:500&ndash;508.
[PubMed]
37.
Martin SL, Maniero GD, Carey C, Hand SC: Reversible depression of oxygen consumption in isolated liver mitochondria during hibernation. Physiol Biochem Zool 1999;72:255&ndash;264.
[PubMed]
38.
Heldmaier G, Ortmann S, Elvert R: Natural hypometabolism during hibernation and daily torpor in mammals. Respir Physiol Neurobiol 2004;141:317&ndash;329.
[PubMed]
39.
Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I: Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988;82:322&ndash;330.
[PubMed]
40.
Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol 1996;7:653&ndash;660.
[PubMed]
41.
Fenster BE, Tsao PS, Rockson SG: Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003;146:218&ndash;226.
[PubMed]
You do not currently have access to this content.